Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Terminated 3Completed 2

Sponsor Class

OTHER 2INDUSTRY 2NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5Thoracic 2Genitourinary 2Gastrointestinal 2Sarcoma 1Gynecologic 1

Conditions

Breast Neoplasms 5Glioblastoma 4Oligodendroglioma 3Gliosarcoma 3Glioma 3Brain Neoplasms 3Astrocytoma 3Prostatic Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Central Nervous System Neoplasms 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Supratentorial Neoplasms 1Stomach Neoplasms 1Spinal Cord Neoplasms 1Sarcoma 1Rhabdoid Tumor 1Rectal Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Optic Nerve Glioma 1Myelodysplastic Syndromes 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1

Interventions

Trastuzumab 594Paclitaxel 561Cyclophosphamide 545Docetaxel 478Capecitabine 387Letrozole 350Fulvestrant 310Doxorubicin 285Carboplatin 277Tamoxifen 257Anastrozole 219exemestane 211Epirubicin 210Radiotherapy 197Bevacizumab 189pertuzumab 175Gemcitabine 163Vinorelbine 162pembrolizumab 161Lapatinib 161palbociclib 152Exercise 132Fluorouracil 118Albumin-Bound Paclitaxel 116eribulin 108Magnetic Resonance Spectroscopy 108130-nm albumin-bound paclitaxel 107Everolimus 103Taxes 96Cisplatin 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Breast Neoplasms × lonafarnib × Clear all
NCT00773474 2016-02-18

Lonafarnib in Metastatic Breast Cancer

Hoosier Cancer Research Network

Phase 2 Terminated
29 enrolled 11 charts
Breast

Breast Neoplasms

NCT00081510 2015-04-15

Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)

Merck Sharp & Dohme LLC

Phase 2 Completed
110 enrolled
Breast

Breast Neoplasms

NCT00539968 2015-02-05

A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)

Merck Sharp & Dohme LLC

Phase 1/2 Terminated
5 enrolled
BreastGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT00288444 2012-12-18

Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer

Emory University

Phase 1 Terminated
38 enrolled
BreastGastrointestinalGenitourinarySarcomaThoracic

Breast Neoplasms, Lung Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT00068757 2012-09-12

Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 1 Completed
23 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡